Pauwels E K, Sturm E J, Bombardieri E, Cleton F J, Stokkel M P
Leiden University Medical Centre, Division of Nuclear Medicine, The Netherlands.
J Cancer Res Clin Oncol. 2000 Oct;126(10):549-59. doi: 10.1007/pl00008465.
Over the past decades, Positron Emission Tomography has opened a new field of imaging. Nowadays, this technique is being used for diagnosing, staging disease as well as for prognostic stratification and monitoring therapy. In this respect, [18F]fluorodeoxyglucose (FdGlc) is by far the most commonly used PET agent. Many factors have been identified being responsible for a high uptake of this agent in malignancy. However, additional factors such as tumour treatment may interfere with the uptake mechanism. Knowledge of all these factors is a prerequisite for an optimal interpretation of PET studies and, consequently, for a reliable judgement of tumour status. In this article, a review is given of the factors influencing FdGlc uptake and the implications for clinical studies.
在过去几十年里，正电子发射断层扫描（PET）开辟了一个新的成像领域。如今，这项技术被用于疾病的诊断、分期，以及预后分层和治疗监测。在这方面，[18F]氟脱氧葡萄糖（FdGlc）是目前最常用的PET显像剂。许多因素已被确定与该显像剂在恶性肿瘤中的高摄取有关。然而，诸如肿瘤治疗等其他因素可能会干扰摄取机制。了解所有这些因素是对PET研究进行最佳解读的前提条件，因此也是可靠判断肿瘤状态的前提条件。本文对影响FdGlc摄取的因素及其对临床研究的意义进行综述。
